化合物 BCI-215|T7323|TargetMol

BCI-215
1245792-67-9

￥453 1mg 起订

￥937 5mg 起订

￥1530 10mg 起订

上海更新日期：2024-09-30

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 BCI-215

英文名称：: BCI-215

CAS号：: 1245792-67-9

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: ≥95%

产品类别：: 抑制剂

货号：: T7323

Product Introduction

Bioactivity

名称	BCI-215
描述	BCI-215 causes selective cancer cell cytotoxicity in part through non-redox-mediated activation of MAPK signaling
细胞实验	Peripheral blood mononuclear cells were obtained from healthy volunteers. Cells were cultured in RPMI 1640 supplemented with 10% fetal calf serum, 1% glutamine, and 1% penicillin/streptomycin, and stimulated with 6,000 IU of Interleukin 2 for 24 hours. After incubation, cells were washed with PBS and counted. In parallel, MDA-MB-231 cells were pretreated in a 384-well plate with vehicle or BCI-215 (3 μM). After 24 hours in culture, medium was replaced and peripheral blood mononuclear cells (PBMCs) added in 2-fold serial dilutions starting with a 50-fold excess of PBMCs in triplicate. After 24 hours of coculture, cells were fixed with formaldehyde/Hoechst 33342, washed twice with PBS, and imaged on the ArrayScan II. Cancer cells were identified by their larger nuclei compared with PBMCs, setting a size gate in the Hoechst channel. In experiments with chemotherapeutics, cells carrying a biosensor consisting of a mitochondrial targeting sequence derived from cytochrome c oxidase VIII linked to GFP that is a surrogate for cytochrome c release from mitochondria were pretreated for 24 hours with cisplatin (2 μM) or doxorubicin (400 nM), exposed to LAK, and cancer cells were identified and quantified by green fluorescence. Cell densities were normalized to those in the absence of PBMCs. Mean cell densities from multiple independent experiments were averaged and plotted in GraphPad Prism version 7.00[1].
体外活性	在MDA-MB-231人类乳腺癌细胞中，BCI-215抑制了细胞迁移能力，诱导了细胞凋亡而非初级坏死，并增强了细胞对淋巴因子激活的杀手细胞活性。从机制上看，BCI-215在无活性氧物种的情况下，诱导了细胞外信号调节激酶（ERK）、p38和c-Jun N末端激酶（JNK）的快速持续磷酸化，其毒性通过抑制p38得到部分解救，但抑制JNK或ERK无效。BCI-215还超激活了MKK4/SEK1，暗示了应激反应的激活[1]。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 3.96 mg/mL (10 mM), Sonication is recommended.
关键字	specificity \| BCI 215 \| Phosphatase \| DUSP-MKP \| inhibit \| Inhibitor \| MAPK \| BCI215 \| BCI-215 \| dual
相关产品	Sodium orthovanadate \| Stearic acid \| Tartaric acid disodium dihydrate \| PTP1B-IN-22 \| Cyclosporine \| Cis-5-Norbornene-exo-2,3-dicarboxylic Anhydride \| L-Ascorbic acid 2-phosphate magnesium \| CaMKP Inhibitor \| Idoxuridine \| β-Glycerophosphate disodium salt pentahydrate \| Tetramisole hydrochloride \| Trimyristin
相关库	抑制剂库 \| 经典已知活性库 \| 抗癌活性化合物库 \| 抗癌化合物库 \| 已知活性化合物库 \| 磷酸酶抑制剂化合物库 \| 代谢化合物库 \| NO PAINS 化合物库 \| 糖代谢化合物库

BCI-215|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 BCI-215相关厂家报价

聚酯PET抗氧化剂215
青岛杰得佳新材料科技有限公司 VIP
2024-10-10
￥38

S-215抗氧剂
广州对德化工有限公司
2024-11-07
￥20

酸性红215
河南沃咖斯生物科技有限公司 VIP
2024-11-29
询价

BCI-215
台州市科瑞生物技术有限公司 VIP
2024-09-30
询价

内容声明